诺维本联合顺铂治疗NSCLC90例临床观察  

Combination chemotherapy with navelbine and cisplatin in the treatment of 90 patients with non small cell lung cancer

作　　者：朱允中[1] 徐丽焱[1] 史鹤玲[1] 刘喆[1] 

机构地区：[1]北京市结核病胸部肿瘤医院肿瘤科,101149

出　　处：《中国肺癌杂志》2000年第2期121-122,共2页Chinese Journal of Lung Cancer

摘　　要：目的　评价诺维本 (navelbine ,NVB)与顺铂 (cisplatin ,DDP)联合治疗非小细胞肺癌 (non smallcelllungcancer ,NSCLC)的疗效及毒副反应。方法　自 1994年 4月至 1998年 12月对 90例中晚期NSCLC患者进行NVB +DDP联合化疗 ,第 1、8天用NVB 2 5～ 3 0mg/m2 ,第 3天用DDP 60～ 80mg/m2 ,每 2 8天为一周期 ,每例患者至少完成 2周期化疗方可评价疗效。结果　全组总有效率为 2 7.8% ( 2 5 /90 ) ,其中Ⅲ期患者总有效率为 41.0 % ( 16/3 9) ,而Ⅳ期有效率仅为 16.5 % ( 8/48) ,两组间有显著性差异 (P <0 .0 0 5 )。本方案主要的副反应是白细胞降低和静脉炎 ,Ⅲ和Ⅳ度白细胞降低发生率分别为 2 0 %和18.9% ,静脉炎发生率为 3 2 .2 % ( 2 9/90 )。通过G CSF的辅助治疗 ,本组无一例因重度骨髓抑制而危及生命 ,而改变NVB的给药方法可减少静脉炎的发生率。结论　NVB +DDP方案治疗NSCLC有较好的疗效 ,白细胞降低是其主要的剂量限制性毒性。Objective To evaluate the efficacy and adverse reactions of navelbine(NVB) and cisplatin(DDP) in the treatment of non small cell lung cancer(NSCLC). Methods From April 1994 to December 1998, 90 patients with NSCLC were treated with NVB plus DDP. NVB was given at a dose of 25 to 30?mg/m 2 on days 1 and 8; DDP 60 to 80?mg/m 2 on day 3. The schedule was repeated every 28 days, with at least two cycles. Results The overall response rate was 27.8%(25/90) and 41.0%(16/39) for stage Ⅲ and only 16.5%(8/48) for stage Ⅳ. The difference in the response rate of the two groups was statistically significant(P<0.005). The main adverse reactions were leukopenia and phlebitis. The prevalence of grade Ⅲ and Ⅳ leukopenia was 20% and 18.9%, respectively. Supporting by G CSF, no fatal complication was observed in this study. The prevalence of phlebitis was 32.2% (29/90) and could be decreased significantly with the improvement of the way of NVB adminstration. Conclusion The regimen of NVB plus DDP is an effective method to treat NSCLC and its dose limiting toxicity was leukopenia.

关 键 词：非小细胞癌 诺维本 顺铂 联合用药 

分 类 号：R730.5[医药卫生—肿瘤]